Cilostazol induced migraine does not respond to sumatriptan in a double blind trial-Reference-Cited by-同舟云学术

Cilostazol induced migraine does not respond to sumatriptan in a double blind trial

Published:2018-02-02 Issue:1 Volume:19 Page:
ISSN:1129-2369
Container-title:The Journal of Headache and Pain
language:en
Short-container-title:J Headache Pain

Author:

Falkenberg Katrine,Dunga Bára Óladóttir á,Guo Song,Ashina Messoud,Olesen Jes

Funder

Candys Foundation

Migraine Research Foundation

European Union’s Seventh Framework program

Publisher

Springer Science and Business Media LLC

Subject

Anesthesiology and Pain Medicine,Neurology (clinical),General Medicine

Link

http://link.springer.com/article/10.1186/s10194-018-0841-7/fulltext.html

Reference21 articles.

1. Hansen EK, Olesen J (2017) Towards a pragmatic human migraine model for drug testing: 2. Isosorbide-5-mononitrate in healthy individuals. Cephalalgia 37:11–19

2. Hansen EK, Guo S, Ashina M et al (2016) Toward a pragmatic migraine model for drug testing: I. Cilostazol in healthy volunteers. Cephalalgia 36:172–178

3. Guo S, Olesen J, Ashina M (2014) Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. Brain 137:2951–2959

4. Khan S, Deen M, Hougaard A et al (2017) Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol. Cephalalgia 033310241771975

5. National Center for clinical trial registrations. Raske forsøgspersoner søges til migræneforsøg. www.forsøgsperson.dk, (2017, Accessed 28 Aug 2017).

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of PDE-3 inhibition in persistent post-traumatic headache: evidence of cAMP-dependent signaling;The Journal of Headache and Pain;2024-04-17

2. Pathophysiology of Migraine;CONTINUUM: Lifelong Learning in Neurology;2024-04

3. Real-World Safety and Effectiveness of Controlled-Release Cilostazol in Patients with Symptomatic Peripheral Artery Disease;Clinical Drug Investigation;2023-08-31

4. Future targets for migraine treatment beyond CGRP;The Journal of Headache and Pain;2023-06-28

5. Inhibiting neuronal AC1 for treating anxiety and headache in the animal model of migraine;iScience;2023-06